共 151 条
[1]
Hodge JA(2016)The mechanism of action of tofacitinib—an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis Clin Exp Rheumatol 34 318-328
[2]
Kawabata TT(2017)JAK inhibition as a therapeutic strategy for immune and inflammatory diseases Nat Rev Drug Discov 17 78-2311
[3]
Krishnaswami S(2018)In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) BMC Rheumatol 2 23-2512
[4]
Clark JD(2019)Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study Lancet 393 2303-992
[5]
Telliez JB(2018)Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 391 2503-95
[6]
Dowty ME(2018)A phase 2b/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective jak1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs Ann Rheum Dis 77 991-570
[7]
Schwartz DM(2017)Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study Ann Rheum Dis 76 88-261
[8]
Kanno Y(2013)Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study Arthritis Rheum 65 559-1800
[9]
Villarino A(2013)Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial Ann Intern Med 159 253-662
[10]
Ward M(2019)Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind randomized controlled trial Arthritis Rheumatol 71 1788-468